Association of Distance to Treatment Facility With Survival and Quality Outcomes After Radical Cystectomy: A Multi-Institutional Study

Ahmed Q. Haddad, Ryan Hutchinson, Erika L. Wood, Gus Miranda, Boris Gershman, Jamie Messer, Robert Svatek, Peter C. Black, Stephen A. Boorjian, Jay Shah, Siamak Daneshmand, Yair Lotan

Research output: Contribution to journalArticlepeer-review

13 Scopus citations

Abstract

Micro-Abstract In a large multi-institutional cohort, patients distant to a tertiary care center had increased usage of neoadjuvant chemotherapy, a shorter time from diagnosis to surgery, and no difference in survival outcomes compared with patients who resided near to the facility. Thus, referring patients across the geographic distances observed in the present study did not appear to compromise patient care. Background We sought to determine the effect of the travel distance on mortality and quality outcomes after radical cystectomy in a large multi-institutional cohort. Patients and Methods A total of 3957 patients who had undergone radical cystectomy for urothelial carcinoma at 6 North American tertiary care institutions were included. The association of travel distance with quality-of-care endpoints, 90-day mortality, and long-term survival were evaluated. Results The median patient age was 69 years (interquartile range, 61-76 years), and most patients were men (80%). Most patients had clinical stage T2 (45.2%) and T1 (24.7%) tumors. The median distance to the treatment facility was 102.9 miles (interquartile range, 24-271 miles). Patients residing in the first quartile of travel distance to treatment facility (< 24 miles) had lower usage of neoadjuvant chemotherapy compared with patients in the fourth distance quartile (adjusted odds ratio, 1.58; 95% confidence interval, 1.22-2.05; P =.001). Patients in the first distance quartile were also less likely to experience a delay in time to cystectomy (> 3 months) compared with patients with a greater travel distance (adjusted odds ratio, 0.673; 95% confidence interval, 0.532-0.851). Distance to the treatment facility was not associated with 90-day mortality or cancer-specific or all-cause mortality on multivariate analysis. Conclusion Despite the potential health care disparities for bladder cancer patients residing distant to a regional surgical oncology facility, the study results suggest that the travel distance is not a barrier to appropriate oncologic care at regional tertiary care centers.

Original languageEnglish (US)
Pages (from-to)689-695.e2
JournalClinical Genitourinary Cancer
Volume15
Issue number6
DOIs
StatePublished - Dec 2017

Keywords

  • Bladder cancer
  • Morbidity
  • Neoadjuvant chemotherapy
  • Regionalization
  • Travel

ASJC Scopus subject areas

  • Urology
  • Oncology

Fingerprint

Dive into the research topics of 'Association of Distance to Treatment Facility With Survival and Quality Outcomes After Radical Cystectomy: A Multi-Institutional Study'. Together they form a unique fingerprint.

Cite this